Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-negative,ER-positive) and gBRCA or HDR-positive Metastatic Breast Cancer(LUZERN)
Conditions: Breast Cancer; Breast Cancer Metastatic Intervention: Drug: Niraparib 100 MG Sponsors: MedSIR; GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials